While in vitro and animal studies suggest that GLP-1 receptor agonists (GLP-1RAs) may enhance bone health by reducing bone resorption, stimulating new bone formation, and increasing bone mineral density (BMD), human studies, particularly in individuals with T2DM, have yielded conflicting results regarding bone markers, BMD, and fragility fractures [12–14]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.